Merrion Pharmaceuticals Plc was admitted to the IEX today

Dec 2007
Merrion Pharmaceuticals Plc was admitted to the IEX today and commenced unconditional trading.

John Lynch CEO of Merrion Pharmaceuticals Plc, said, ″we are very pleased to have achieved admission to the IEX today. We look forward to developing our range of drug products and will use the majority of net proceeds from the IEX placing to fund clinical trials and pre-clinical testing and other research and development testing″

Goodbody corporate finance is the IEX advisor and Goodbody Stockbrokers is the IEX broker to Merrion Pharmaceuticals. Commenting on the announcement Finbarr Griffen Director of Corporate Finance said, ″The admission for the company today represents a significant milestone for the company demonstrating strong shareholder support in what are difficult markets. The admission provides a platform for further growth for the company whilst also providing greater liquidity to existing shareholders″.

Merrion Pharmaceuticals Plc was founded by Growcorp Group Limited in 2004 following its acquisition from Elan of Intellectual Property. Growcorp built a business plan around the IP and hired the senior management. Growcorp Managing Director Fintan Maher said ″we are delighted with today′s successful IPO, Merrion Pharmaceuticals Eur 70 Million market capitalisation represents an excellent return on Growcorp Groups original Eur 2 Million investment, we look forward to the continued successful development of the company″.

Fintan P. Maher

Managing Director
Growcorp Group Ltd
3015 Citywest, Dublin 24
Ireland
+353 1 466 1000
(f)+353 1 4661002

Copyright 2007 Growcorp Group. All Rights Reserved.
Office: Growcorp Group Limited, 3015 Lake Drive, Citywest Campus, Citywest, Dublin 24 | Telephone: +353 1 4661000 | Fax: +353 1 4661002
2009
Merrion’s new facility at Citywest officially opened by Minister Harney 29 October 2009. Growcorp the founding Shareholder of Merrion Pharmaceuticals the Irish Stock Exchange listed company today announced it was delighted with the opening by Merrion Pharmaceuticals of it new facility in Citywest.

Merrion Pharmaceuticals has purchased a new facility in order to expand its current research and development operations.
Merrion has acquired a 26,684 square foot pharmaceutical facility in Citywest, Co Dublin.

Merrion Lands Second $58M Deal. Irish drug development firm Merrion Pharmaceuticals has inked a second deal with Denmark-based medicine supplier Novo Nordisk that could be worth up to $58m (Eur44m) for the Dublin-headquartered company. Merrion was founded by Growcorp Group Ltd when it acquired extensive IP from Elan in early 2003 following over one years due diligence. Growcorp then developed a business plan and hired all senior management.

2008
Galway and Dublin. Wednesday, 3rd December, 2008: Growcorp Group, the Irish investment vehicle, will earn over Eur 7m following the acquisition this week of Irish theranoistic company Neutekbio by Danish biotechnology development company Merrion Pharmaceuticals has signed a multi-million euro deal with Novo Nordisk to develop oral diabetes products.

2008
DUBLIN, Ireland, Nov 5, 2008 an international specialty pharmaceutical company, today announced that it has been awarded the Frost & Sullivan 2008 Osteoporosis Technology Innovation of the Year Award

2008
DUBLIN, Ireland, Nov 5, 2008 an international specialty pharmaceutical company, today announced that it has been awarded the Frost & Sullivan 2008 Osteoporosis Technology Innovation of the Year Award

2008
Merrion Pharmaceuticals the TCD based Irish American company has confirmed that it has begun a joint feasibility study on oral drug delivery with Swiss based multinational Ferring Pharmaceuticals.

2007
Merrion Pharmaceuticals Plc was admitted to the IEX today and commenced
unconditional trading.........